•  
  •  
  •  
  •  

2025-10-02 07:42:11

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue

Keywords Selected:  AstecLifeSciences

Stock Report

  • Astec LifeSciences Ltd consolidated Q1FY26 loss at Rs. 33.03 crores
  • Astec LifeSciences Ltd Q4FY25 consolidated loss reduces QoQ to Rs. 16.08 crores
  • Astec LifeSciences Ltd has sold vacant office premises in Mumbai
  • Astec LifeSciences Ltd Q1 FY25 consolidated loss at Rs. 39.72 crores
  • Astec LifeSciences Ltd consolidated Q4FY24 loss at Rs. 97.39 lakhs
  • Astec LifeSciences Ltd Q3 FY24 consolidated loss at Rs. 24.33 crores
  • Astec LifeSciences Ltd posts consolidated Q1FY24 loss of Rs. 8.19 crore
  • Astec Lifesciences Ltd recommends final dividend of Rs. 1.50
  • Astec LifeSciences Ltd reports consolidated loss of Rs. 4.98 crores in Q4FY23
  • Astec LifeSciences launches Adi Godrej Center for Chemical Research and Development
  • Astec LifeSciences Ltd consolidated Q3FY23 PAT slumps to Rs. 83.97 lakhs
  • Astec LifeSciences Ltd consolidated Q2FY23 PAT rises to Rs. 18.30 crores
  • Astec LifeSciences Ltd Q1 FY2023 consolidated net profit falls to Rs. 11.39 crores
  • Astec LifeSciences Ltd recommends final dividend of Rs. 1.50
  • Astec LifeSciences Q4FY2022 consolidated PAT surges to Rs. 43.05 crores
  • ICRA reaffirms rating of Astec LifeSciences Limited
  • Astec LifeSciences' consolidated PAT surges in Q3FY22 to Rs. 24.74 crore
  • Astec LifeSciences Ltd posts Rs. 9.07 crore consolidated PAT in Q2FY22

Latest Post

  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024